Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Esophageal Neoplasms 2Uterine Cervical Neoplasms 1Tissue Adhesions 1Thyroid Neoplasms 1Stomach Neoplasms 1Right Sided Colon Cancer 1Ovarian Neoplasms 1Oligometastatic Non-small Cell Lung Cancer (NSCLC) 1Neoplasms 1Laparoscopy 1Head and Neck Neoplasms 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinosarcoma 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Minimally Invasive Surgical Procedures × Clear all
NCT02463877 2022-09-14

A Minimally-invasive Approach to Cytoreduction and HIPEC for Peritoneal Surface Malignancy

University of California, San Diego

Phase 2 Completed
18 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡